These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10778983)

  • 1. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.
    Krishan A; Sridhar KS; Mou C; Stein WD; Lyubimov E; Hu YP; Fernandez H
    Clin Cancer Res; 2000 Apr; 6(4):1508-17. PubMed ID: 10778983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
    Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
    Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
    Howell SB; Hom D; Sanga R; Vick JS; Abramson IS
    Cancer Res; 1989 Jun; 49(12):3178-83. PubMed ID: 2720673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the modulation of antiblastics cytotoxicity by verapamil and dipyridamole in a human colon carcinoma cell line.
    Berti E; Carrara M; Ragazzi E; D'Ancona S; Berti T
    Int J Oncol; 1999 Jul; 15(1):155-60. PubMed ID: 10375609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of anthracycline retention modulation in human tumor cells.
    Krishan A; Sridhar KS; Davila E; Vogel C; Sternheim W
    Cytometry; 1987 May; 8(3):306-14. PubMed ID: 3595352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
    Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
    Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of the verapamil-induced enhancement of doxorubicin's cytotoxicity from changes in cellular accumulation or retention of doxorubicin in pancreatic cancer cell lines.
    Chang BK; Brenner DE; Gutman R
    Anticancer Res; 1989; 9(2):347-51. PubMed ID: 2751260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high-performance liquid chromatography.
    Mou C; Ganju N; Sridhar KS; Krishan A
    J Chromatogr B Biomed Sci Appl; 1997 Dec; 703(1-2):217-24. PubMed ID: 9448079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo.
    Kusumoto H; Maehara Y; Anai H; Kusumoto T; Sugimachi K
    Cancer Res; 1988 Mar; 48(5):1208-12. PubMed ID: 3342401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipyridamole enhancement of etoposide sensitivity.
    Howell SB; Hom DK; Sanga R; Vick JS; Chan TC
    Cancer Res; 1989 Aug; 49(15):4147-53. PubMed ID: 2545335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
    Zhang Y; Song S; Yang F; Au JL; Wientjes MG
    J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipyridamole potentiates adriamycin cytotoxicity by a mechanism other than inhibiting nucleoside uptake.
    Kusumoto H; Maehara Y; Anai H; Kumashiro R; Sugimachi K
    Anticancer Res; 1991; 11(4):1539-42. PubMed ID: 1746911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C; Wellham LL
    Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F; Duivenvoorden WC; Singh G
    Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.
    Sridhar KS; Krishan A; Samy TS; Duncan RC; Sauerteig A; McPhee GV; Auguste ME; Benedetto PW
    Cancer Chemother Pharmacol; 1994; 34(5):377-84. PubMed ID: 8070004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
    Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
    Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.